Literature DB >> 4073858

Comparison of ceftriaxone and ampicillin plus chloramphenicol for the therapy of acute bacterial meningitis.

J P Bryan, H Rocha, H R da Silva, A Taveres, M A Sande, W M Scheld.   

Abstract

Ceftriaxone, a new third-generation cephalosporin, appears to be promising for the therapy of acute bacterial meningitis. The 90% MBCs of ceftriaxone against 54 recent cerebrospinal fluid isolates of Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae were less than or equal to 0.06 to 0.25 micrograms/ml. We examined the efficacy and safety of ceftriaxone therapy of meningitis in Bahia, Brazil. The study was conducted in two phases; in phase A, ceftriaxone was coadministered with ampicillin. The mean cerebrospinal fluid concentrations of ceftriaxone 24 h after an intravenous dose of 80 mg/kg were 4.2 and 2.3 micrograms/ml on days 4 to 6 and 10 to 12 of therapy, respectively. These concentrations were 8- to more than 100-fold greater than the 90% MBCs against the relevant pathogens. In phase B, ceftriaxone (administered once daily at a dose of 80 mg/kg after an initial dose of 100 mg/kg) was compared with conventional dosages of ampicillin and chloramphenicol in a prospective randomized trial of 36 children and adults with meningitis. The groups were comparable based on clinical, laboratory, and etiological parameters. Ceftriaxone given once daily produced results equivalent to those obtained with ampicillin plus chloramphenicol, as judged by cure rate, case fatality ratio, resolution with sequelae, type and severity of sequelae, time to sterility of cerebrospinal fluid, and potentially drug-related adverse effects. The cerebrospinal fluid bactericidal titers obtained 16 to 24 h after ceftriaxone dosing were usually 1:512 to greater than 1:2,048 even late in the treatment course, compared with values of 1:8 to 1:32 in patients receiving ampicillin plus chloramphenicol. Ceftriaxone clearly deserves further evaluation for the therapy of meningitis; the optimal dose, dosing frequency (every 12 h or every 24 h), and duration of therapy remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4073858      PMCID: PMC180254          DOI: 10.1128/AAC.28.3.361

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  Neonatal salmonella meningitis complicated by cerebral abscesses.

Authors:  S E West; R Goodkin; A M Kaplan
Journal:  West J Med       Date:  1977-08

2.  Meningitis due to Haemophilus influenzae type b resistant to ampicillin and chloramphenicol.

Authors:  N Uchiyama; G R Greene; D B Kitts; L D Thrupp
Journal:  J Pediatr       Date:  1980-09       Impact factor: 4.406

3.  Diffusion of ceftriaxone (Ro 13-9004/001) in the cerebrospinal fluid. Comparison with other beta-lactam antibiotics in dogs with healthy meninges and in dogs with experimental meningitis.

Authors:  B Marchou; M Armengaud
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

Review 4.  Management of bacterial meningitis in infants and children. Current status and future prospects.

Authors:  G H McCracken
Journal:  Am J Med       Date:  1984-05-15       Impact factor: 4.965

5.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

6.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

7.  In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.

Authors:  S Shelton; J D Nelson; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

8.  Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

Authors:  K Stoeckel; P J McNamara; R Brandt; H Plozza-Nottebrock; W H Ziegler
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

9.  Characterization of chloramphenicol-resistant Haemophilus influenzae.

Authors:  M C Roberts; C D Swenson; L M Owens; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

10.  Intravenous cefotaxime in children with bacterial meningitis.

Authors:  B H Belohradsky; K Bruch; D Geiss; D Kafetzis; W Marget; G Peters
Journal:  Lancet       Date:  1980-01-12       Impact factor: 79.321

View more
  11 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis.

Authors:  K Prasad; A Kumar; P K Gupta; T Singhal
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

3.  Novel approaches to therapy of meningitis.

Authors:  G H McCracken
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

Review 4.  Chemotherapy for bacterial infections of the central nervous system.

Authors:  N M Ampel; E L Labadie
Journal:  West J Med       Date:  1987-09

Review 5.  Microbiological investigation of cephalosporins.

Authors:  J M Hamilton-Miller
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 6.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

7.  Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges.

Authors:  R Nau; H W Prange; P Muth; G Mahr; S Menck; H Kolenda; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries?

Authors:  T Duke; A Michael; D Mokela; T Wal; J Reeder
Journal:  Arch Dis Child       Date:  2003-06       Impact factor: 3.791

9.  Therapy of experimental meningitis due to Salmonella enteritidis.

Authors:  J P Bryan; W M Scheld
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.